Effects of HAART on hepatitis C, hepatitis G, and TT virus in multiply coinfected HIV-positive patients with haemophilia

Haemophilia

Volumn 7, Issue 6, 2001, Pages 575-581

  Takamatsu, J ^a   Toyoda, H ^a   Fukuda, Y ^a   Nakano, I ^a   Yokozaki, S ^a   Hayashi, K ^a   Saito, H ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HAART; Hepatitis C virus; Hepatitis G virus; Human immunodeficiency virus; TT virus

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; VIRUS DNA; VIRUS RNA; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AIDS RELATED COMPLEX; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HEMOPHILIA A; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; TIME; TORQUE TENO VIRUS; VIROLOGY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEMOPHILIA; HEPATITIS C; HEPATITIS VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE STATUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUPERINFECTION; VIRUS CONCENTRATION; VIRUS DETECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMORBIDITY; DNA, VIRAL; GB VIRUS C; HEMOPHILIA A; HEPACIVIRUS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; RNA, VIRAL; TIME FACTORS; TORQUE TENO VIRUS; HUMAN; TRANSFUSION-TRANSMITTED VIRUS;

EID: 0035543819     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00567.x     Document Type: Article

References (49)

1. Descriptive epidemiology of HIV/AIDS in Japan. 1985-94
2. Isolation of novel virus-like sequences associated with human hepatitis
3. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent
4. Alphabet of hepatitis viruses
5. A novel DNA virus (TTV) associated with elevated transaminase levels in post-transfusion hepatitis of unknown etiology
6. Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology
7. The acronym TTV
8. Molecular and biophysical characterization of TT virus: Evidence for a new virus family infecting humans
9. Molecular investigation of GB virus C infection in hemophiliacs in Japan
10. GB virus C/hepatitis G virus isolates in Japanese haemophiliacs and their origins
11. Prevalence and persistence of a DNA transfusion-transmitted virus infection in Japanese haemophiliacs
12. Infection with TT virus (TTV), a novel transfusion-transmissible DNA virus, in haemophiliacs and in blood products
13. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
14. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
15. Antiretroviral drugs for AIDS
16. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel
17. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
18. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
19. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
20. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects
21. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients
22. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs
23. Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor
24. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients
25. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region
26. A proposed system for the nomenclature of hepatitis C viral genotypes
27. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene
28. Sequence heterogeneity within the 5′-terminal region of the hepatitis GB virus C genome and evidence for genotypes
29. Very high prevalence of TT virus (TTV) infection in general population of Japan revealed by a new set of PCR primers
30. Real time quantitative PCR
31. Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G
32. Development of a TT virus DNA quantification system using realtime detection PCR
33. Detection of antibodies to a putative hepatitis G virus envelope protein
34. An ELISA for detection of antibodies to the E2 protein of GB virus C
35. Clearance of hepatitis G viremia by high activity antiretroviral therapy in an HIV-positive patient
36. Increased hepatitis C virus RNA levels in haemophiliacs: Relationship to human immunodeficiency virus infection and liver disease
37. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV
38. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: Influence of antiretroviral therapy
39. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection
40. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy
41. Mutation rate of GB virus C/hepatitis G virus over the entire genome and in subgenomic regions
42. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus
43. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection
44. Patterns of hepatitis G viraemia and liver disease in haemophiliacs previously exposed to non-virus inactivated coagulation factor concentrates
45. Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients
46. Influence of CD4+ lymphocyte counts on GB virus C/hepatitis G virus carriership in HIV-positive individuals
47. Correlation of interferon treatment response with GBV-C/HGV genomic RNA and anti-envelope 2 protein antibody
48. Global distribution of transfusion-transmitted virus
49. Prevalence of infection with TT virus (TTV), a novel DNA virus, in healthy Japanese subjects, newborn infants, cord blood and breast milk